CD38 and AL amyloidosis: Although most pharmacokinetic data on daratumumab are derived from studies on multiple myeloma, these findings provide valuable insights into its pharmacokinetic behavior, which is expected to be similar in acute leukemias due to comparable CD38 expression and target-mediated clearance.